Greater availability of real-world data and real-world evidence is rapidly changing the landscape of drug development.

Access to UK Biobank data by researchers based in China has sparked headlines in the UK about potential security concerns, ...

In one move that will please the drug industry, Trump has promised to do away with the detested 'pill penalty', a shorter ...

The policy was the buzz of the International Society for Health Economics and Outcomes Research (ISPOR) annual European ...

The EU approval comes after Eisai and Biogen were given approval for a new once-monthly intravenous maintenance dose of ...

Johnson & Johnson has said it expects to see a $400 million financial hit from President Trump's tariffs, which will be felt ...

Click Therapeutics' digital therapeutic (DTx) CT-132 has been approved by the FDA, becoming the first treatment of its type ...

Join the TPD & Induced Proximity Pharma Partnering Summit to accelerate partnership interest in your protein degradation ...

For decades, treatment options for rare diseases have been limited, often focusing on symptom management rather than ...

For example, if they are trained on data that reflects existing disparities in treatment or demographics, the AI could ...

Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss, but was plagued by ...